Rafael Holdings IncNYSE:RFL
- LAST PRICE1.8101
- TODAY'S CHANGE (%)-0.1399 (-7.1744%)
- Bid / Lots1.8200/ 1
- Ask / Lots1.8500/ 5
- Open / Previous Close1.8000 / 1.9500
- Day Range
- 52 Week Range
- Volume22,707
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | RFL |
|---|---|---|
| 09:32 ET | 19263 | 1.85 |
| 09:35 ET | 500 | 1.805 |
| 09:37 ET | 500 | 1.83 |
| 09:39 ET | 1300 | 1.8101 |
Nov 6, 2024
*DJ Rafael Holdings 4Q Rev $165,000 >RFL, from 7:14PM ET on Wednesday Nov 06, 2024 by Dow Jones
7:14PM ET on Wednesday Nov 06, 2024 by Dow JonesRafael Holdings Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results, from 7:14PM ET on Wednesday Nov 06, 2024 by Dow Jones
7:14PM ET on Wednesday Nov 06, 2024 by Dow Jones
Industry Peers
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Rafael Holdings Inc | 48.2M | -1.5x | --- |
Presidential Realty Corp | 15.3K | 0.1x | --- |
Palmetto Real Estate Trust | 14.2M | 29.4x | +3.53% |
Power REIT | 3.8M | -0.2x | --- |
Medalist Diversified Reit Inc | 13.5M | -8.1x | --- |
Pillarstone Capital REIT | 9.9K | 0.0x | --- |
Company Information
Rafael Holdings, Inc. is a holding company with interests in clinical and early-stage pharmaceutical companies. Its segments include Healthcare, Infusion Technology and Real Estate. The Healthcare segment holds interest in LipoMedix Pharmaceuticals Ltd. (LipoMedix), Barer Institute Inc. (Barer), Cornerstone Pharmaceuticals, Inc. (Cornerstone) and Rafael Medical Devices, LLC. The Real Estate segment consists of the Company’s real estate holdings, which is comprised of a portion of a commercial building in Israel. The Infusion Technology segment holds interest in Day Three Labs, Inc. LipoMedix is a clinical-stage pharmaceutical company. Rafael Medical Devices, LLC, an orthopedic-focused medical device company. Cornerstone Pharmaceuticals, Inc. is a cancer metabolism-based therapeutics company. Cyclo Therapeutics Inc. develops Trappsol Cyclo, which is being evaluated in clinical trials for the treatment of Niemann-Pick Disease Type C1 (NPC).
Contact Information
- Headquarters
- 520 Broad StreetNEWARK, NJ, United States 07120
- Phone
- 212-658-1450
- Fax
- 302-636-5454
Executives
- Executive Chairman of the Board
- Howard Jonas
- President, Chief Executive Officer
- William Conkling
- Chief Financial Officer
- David Polinsky
- Chief Medical Officer
- John Goldberg
- Lead Independent Director
- Stephen Greenberg
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | --- |
|---|---|
Revenue (TTM) | --- |
Shares Outstanding | --- |
Rafael Holdings Inc does not pay a dividend. | |
Beta | --- |
EPS | --- |
Book Value | --- |
P/E Ratio | -1.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
